Our articles keep health professionals up-to-date with the happenings throughout the industry.

Clinical Articles

HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.

HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.

Opioid Analgesic Stewardship in Acute Pain

Opioids are high-risk medicines that are associated with significant harm or death when misused. A report commissioned by the Australian Institute of Health and Welfare (AIHW) highlights the harms caused by opioids. It shows…

Read more

New Therapy for Cystic Fibrosis

From 1 April 2022, a new treatment for cystic fibrosis was listed on the Pharmaceutical Benefits Scheme (PBS). Trikafta® (elexacaftor, tezacaftor + ivacaftor) is an authority required item supplied under the Section 100 Highly…

Read more

Seasonal Influenza Vaccination

The Australian Technical Advisory Group on Immunisation (ATAGI) has published advice on the use of seasonal influenza vaccines for 2022. Some of the key points include: Annual vaccination is recommended for all people six…

Read more

Paroxysmal Nocturnal Haemoglobinuria

From 1 March 2022, eculizumab and ravulizumab are available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). This is an extension of indications for eculizumab which was listed…

Read more

Aged Care and Chemical Restraint

Restrictive practice is an intervention or practice that restricts the rights or freedom of movement of the person. There are five restrictive practices in aged care – chemical restraint, environmental restraint, mechanical restraint, physical…

Read more

Molnupiravir for COVID-19

On 1 March 2022, molnupiravir became the first COVID-19 antiviral to be available on the Pharmaceutical Benefits Scheme (PBS). Molnupiravir is provisionally approved for the treatment of adults with COVID-19 who are at increased…

Read more
Load More